| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 30 May 2025 | 21 May 2025 |
| Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 inter alia to consider and approve Meeting of the Board of Directors of Parmax Pharma Limited will be held on Friday 30th May 2025 at 4.00 PM inter alia to consider approve the Audited Financial Results of the quarter and Financial year ended on 31st March 2025 | ||
| Board Meeting | 14 Feb 2025 | 6 Feb 2025 |
| Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2025 inter alia to consider and approve the Meeting of the Board of Directors of Parmax Pharma Limited will be held on Friday 14th February 2024 at 3:00 PM inter alia to consider approve the Un-Audited Financial Results for the quarter ended 31st December 2024 and to discuss any other matter with the permission of Board. Pursuant to the provisions of Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company at its meeting held today, i.e. November 14, 2024 inter alia has considered and approved: 1. The Unaudited Financial Results of the Company for the quarter and half year ended on September 30, 2024. The same has also been reviewed by the Audit Committee in its meeting held today. 2. B A Shah S R Mehta & Co., Statutory Auditors of the Company have carried out the Limited Review of the Unaudited Financial Results for the quarter and half year ended on September 30, 2024 and the Board has also taken on record their Limited Review Report on the said Results. (As Per BSE Announcement Dated on 14.02.2025) | ||
| Board Meeting | 14 Nov 2024 | 6 Nov 2024 |
| Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve The meeting of the Board of Directors of PARMAX PHARMA LIMITED will be held on Thursday 14th November 2024 at 4.00 PM inter alia to consider approve the Unaudited Financial Results for the Quarter ended on 30th September 2024. Pursuant to the provisions of Regulation 30 and 33 of the SEBI (LODR) Regulations, 2015, the Board of Directors of the company at its meeting held on 14th November, 2024 inter alia has considered and approved the Unaudited Financial Results of the company for the quarter and half year ended on September, 30, 2024, B A Shah S R Mehta & Co. Statutory Auditors have carried out the limited review of the Unaudited Financial Results for the quarter and half year ended on 30.09.2024 and board has also taken on record their Limited Review Report on the said results. (As Per BSE Announcement dated on 15.11.2024) we would like to inform you that the financial statements for the period ending on September 30, 2024 were duly prepared and approved at the scheduled meeting of Board of Directors held on Thursday, 14th November, 2024. We apologize for this delay in filing , due to circumstances beyond our control. We request you to condone this delay filing as all processes and approvals were completed within the required timeline. (As Per BSE Announcement Dated on 02.12.2024) | ||
| Board Meeting | 14 Aug 2024 | 6 Aug 2024 |
| Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2024 inter alia to consider and approve Unaudited financial results for the quarter ended on 30th June 2024 and to discuss any other matter with the permission of the board. The board of directors of Parmax Pharma Limited at its meeting held today i.e. 14/08/2024 inter alia has considered and approved unaudited financial statement for the quarter ended on 30.06.2024 along with the Limited Review Report provided by statutory auditor of the company, Appointed Samsad Alam Khan as a secretarial auditor for the FY 2024-25, Appointed B A SHAH & ASSOCIATES as an Internal Auditor of the company for FY2024-25. (As per BSE Announcement dated on 14/08/2024) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.